COPENHAGEN, NOVEMBER 01 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the U.S Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) approval of AntibioTx’s ATx201 for treatment of microbiome related skin disorders.
“The FDA approval of our IND is very well-timed since we are ready to initiate studies in North America” said Dr. Lutz Wevelsiep VP of Drug Regulatory Affairs of AntibioTx” The approval to conduct studies in the US has been a key prioritization for a long time and therefore this is a fundamental milestone for AntibioTx”.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
